• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    6/11/24 4:31:35 PM ET
    $AMIX
    $ANL
    $BSGM
    $CAPR
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMIX alert in real time by email

    Gainers

    • Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 11.1% to $1.3 during Tuesday's after-market session. The company's market cap stands at $24.4 million.
    • Unicycive Therapeutics (NASDAQ:UNCY) stock increased by 6.09% to $0.69. The company's market cap stands at $26.1 million.
    • Venus Concept (NASDAQ:VERO) stock increased by 5.71% to $1.11. The company's market cap stands at $7.0 million.
    • Gossamer Bio (NASDAQ:GOSS) stock moved upwards by 4.99% to $0.54. The market value of their outstanding shares is at $121.2 million.
    • Capricor Therapeutics (NASDAQ:CAPR) stock moved upwards by 4.86% to $5.82. The market value of their outstanding shares is at $185.1 million.
    • Poseida Therapeutics (NASDAQ:PSTX) stock moved upwards by 4.72% to $2.88. The market value of their outstanding shares is at $279.2 million.

    Losers

    • Calidi Biotherapeutics (AMEX:CLDI) shares fell 15.3% to $0.23 during Tuesday's after-market session. The company's market cap stands at $14.6 million.
    • BioSig Technologies (NASDAQ:BSGM) stock decreased by 14.88% to $0.4. The company's market cap stands at $5.6 million.
    • ThermoGenesis Holdings (NASDAQ:THMO) shares decreased by 14.12% to $0.46. The market value of their outstanding shares is at $3.6 million.
    • Adlai Nortye (NASDAQ:ANL) stock decreased by 11.5% to $3.31. The company's market cap stands at $122.1 million.
    • Avid Bioservices (NASDAQ:CDMO) stock declined by 8.89% to $7.28. The company's market cap stands at $462.1 million.
    • Immuneering (NASDAQ:IMRX) shares decreased by 8.29% to $1.55. The company's market cap stands at $45.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AMIX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMIX
    $ANL
    $BSGM
    $CAPR

    CompanyDatePrice TargetRatingAnalyst
    Gossamer Bio Inc.
    $GOSS
    3/23/2026Overweight → Neutral
    Cantor Fitzgerald
    Adlai Nortye Ltd.
    $ANL
    3/20/2026$23.00Outperform
    Leerink Partners
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$1.00Outperform → Neutral
    Wedbush
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$0.30Overweight → Equal Weight
    Barclays
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$1.00Outperform → Market Perform
    Leerink Partners
    Adlai Nortye Ltd.
    $ANL
    2/13/2026$16.00Neutral → Buy
    H.C. Wainwright
    Gossamer Bio Inc.
    $GOSS
    1/28/2026$9.00Overweight
    Barclays
    Immuneering Corporation
    $IMRX
    10/31/2025$15.00Outperform
    Leerink Partners
    More analyst ratings

    $AMIX
    $ANL
    $BSGM
    $CAPR
    SEC Filings

    View All

    SEC Form 8-K filed by Unicycive Therapeutics Inc.

    8-K - Unicycive Therapeutics, Inc. (0001766140) (Filer)

    4/6/26 9:11:55 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Calidi Biotherapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

    4/2/26 5:00:27 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Autonomix Medical Inc.

    S-8 - Autonomix Medical, Inc. (0001617867) (Filer)

    4/2/26 5:00:32 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    $AMIX
    $ANL
    $BSGM
    $CAPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business Officer Brakewood Harold Eugene bought $24,990 worth of shares (5,250 units at $4.76), increasing direct ownership by 91% to 11,050 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/21/26 9:09:57 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Schall Thomas J. bought $101,041 worth of shares (21,645 units at $4.67), increasing direct ownership by 41% to 74,530 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/20/26 9:17:29 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF SCIENTIFIC OFFICER Hall Brett Matthew bought $10,502 worth of shares (2,298 units at $4.57), increasing direct ownership by 0.61% to 376,496 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/16/26 4:07:43 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMIX
    $ANL
    $BSGM
    $CAPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Sabar Karimah Es

    4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

    4/3/26 5:00:07 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Sabar Karimah Es

    4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

    4/1/26 8:00:12 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Krasney Karen

    4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

    4/1/26 8:00:15 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMIX
    $ANL
    $BSGM
    $CAPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform's Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy

    SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American Society of Gene and Cell Therapy (ASGCT) annual meeting in Boston, Massachusetts on May 14, 2026. The Company will present data on its RedTail platform. RedTail is Calidi's systemically delivered virotherapy platform designed to selectively target tumors, remodel the tumor microenvironment (TME), and enable high-level expression of therapeutic genetic payloads directly at the tumor site while limiting peripheral exposure. Data presented at the ASGCT meeting

    4/7/26 8:00:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference

    NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that Ben Zeskind, Chief Executive Officer, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 3:45 p.m. ET. The fireside chat will be webcast live and archived in the Investor Relations section of Immuneering's website at Events & Presentations | Immuneering Corporation. About ImmuneeringImmuneering is a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive. The Company

    4/6/26 4:05:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Venus Concept Announces Completion of Common Stock Sale and Short-Form Merger

    TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company"), a global medical aesthetic technology leader, today announced the successful completion by affiliates of Madryn Asset Management, LP ("Madryn") of a short-form merger transaction, pursuant to which 100% ownership of the Company's common stock is now consolidated under funds managed by Madryn (the "Short-form Merger"). The Short-form Merger was consummated on March 30, 2026, and the Company is now privately held by Madryn. All common shares outstanding prior to the Short-form Merger (other than shares held directly or indirectly by Madryn) have been converted, subject to appraisal rights, into

    4/1/26 9:02:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $AMIX
    $ANL
    $BSGM
    $CAPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Gossamer Bio downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Gossamer Bio from Overweight to Neutral

    3/23/26 8:26:50 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Adlai Nortye Ltd. with a new price target

    Leerink Partners initiated coverage of Adlai Nortye Ltd. with a rating of Outperform and set a new price target of $23.00

    3/20/26 8:35:32 AM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio downgraded by Wedbush with a new price target

    Wedbush downgraded Gossamer Bio from Outperform to Neutral and set a new price target of $1.00

    2/24/26 8:01:18 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMIX
    $ANL
    $BSGM
    $CAPR
    Leadership Updates

    Live Leadership Updates

    View All

    Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026

    Company intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and targeted genetic medicine engineered to deliver high concentrations of IL-15 superagonist to the tumor microenvironment in patients with metastatic disease.Calidi expects to present proof of concept data demonstrating the versatility of the RedTail platform and expanding its oncology platform with new payloads including the simultaneous delivery of tumor-localized BiTEs alongside T-cell amplifiers.Calidi expects to present proof of concept data demonstrating the applicability of the RedTail platform in non-oncology indications. SAN DIEGO, Jan. 28, 2026 (GLOBE NEWSWIRE) --

    1/28/26 8:00:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

    NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the appointment of Thomas J. Schall, Ph.D., to Chairman of the Board of Directors. Dr. Schall is a renowned biotech executive and scientist with more than 30 years of leadership in drug discovery and development. He is best known as the founder and longtime CEO and Chairman of ChemoCentryx, where he led the development and eventual FDA approval of Tavneos®, a first-in-class oral therapy for ANCA-associated vasculitis. Under his leadership, ChemoCentryx was acquired by Amgen in 2022 for nearly $4 billion. His career

    9/16/25 7:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

    BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema, Ph.D. as Chief Executive Officer of ImageneBio ("Imagene"), of the combined company after the anticipated closing. "We are thrilled to welcome Dr. Yarema to the team. Kristin is bringing expertise to the team that will push the company, and our lead program, IMG-007, towards significant milestones," commented David Bonita, an Ikena director and a continuing board member of the combined company. "Her experience as a public company CEO and commercial leadership are valuable additions to this team.

    7/23/25 9:00:00 AM ET
    $IKNA
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMIX
    $ANL
    $BSGM
    $CAPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Avid Bioservices Inc.

    SC 13G - Avid Bioservices, Inc. (0000704562) (Subject)

    12/13/24 10:53:25 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Autonomix Medical Inc.

    SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

    12/3/24 6:17:58 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Poseida Therapeutics Inc.

    SC 13D/A - Poseida Therapeutics, Inc. (0001661460) (Subject)

    11/27/24 7:01:59 PM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMIX
    $ANL
    $BSGM
    $CAPR
    Financials

    Live finance-specific insights

    View All

    Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

    Oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission under review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026Commercial readiness activities ongoing in anticipation of potential commercial launch of OLC in 3Q26As of March 30, 2026 unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, with expected runway into 2027 LOS ALTOS, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended D

    3/30/26 7:05:00 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

    - Following PROSERA Phase 3 topline results, the Company is focused on evaluating the totality of the dataset, engaging with the FDA, and assessing strategic options and capital allocation - - Enrollment in the Phase 3 SERANATA Study in PH-ILD has been paused while the Company evaluates implications of PROSERA results - - The Company implemented a reduction in force to align resources with near-term priorities - - Cash, cash equivalents and marketable securities totaled $137 million at year-end 2025 - Gossamer Bio, Inc. (NASDAQ:GOSS), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH)

    3/17/26 4:01:00 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12

    – Company to Host Conference Call on March 12, 2026, at 4:30 p.m. ET – SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2025, after the market close on Thursday, March 12, 2026. Management will host a conference call and webcast at 4:30 p.m. ET that same day. Title:Capricor Therapeutics Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update Conference Call and Webcast  Date:Thursday, March 12, 2026

    3/9/26 8:30:00 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMIX
    $ANL
    $BSGM
    $CAPR
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

    Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

    6/21/24 3:17:31 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care